{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-005761","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.919331+00:00","generated_at":"2026-06-27T03:06:14.080550+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Vivos Therapeutics terminates Chief Medical Officer Dr. G. Dave Singh for cause, effective March 1, 2022","bullets":["Dr. Singh was terminated for cause per his employment agreement dated October 9, 2020.","He had been on sabbatical since September 2021 as Adjunct Professor at Stanford University.","Company has reallocated his responsibilities to other personnel and expects no significant operational impact.","Dr. Singh is no longer affiliated with Vivos as of March 1, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-005761","json":"https://secwatch.observer/filing/0001493152-22-005761.json","markdown":"https://secwatch.observer/filing/0001493152-22-005761.md","text":"https://secwatch.observer/filing/0001493152-22-005761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222005761/0001493152-22-005761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222005761/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:06:14.080550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f78e4f32e1","claim":"Dr. G. Dave Singh was terminated as Chief Medical Officer at Vivos Therapeutics, Inc..","evidence_excerpt":"provided Dr. G. Dave Singh, the Company’s Chief Medical Officer (“Dr. Singh”), with notice of termination of his employment with the Company “for cause” pursuant to the terms Dr. Singh’s employment agreement with the Company, dated October 9, 2020.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315222005761/0001493152-22-005761-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}